Quadrature Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Quadrature Capital’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.2M	Buy	55,823 +43,436	+351%	+$665K	0.01%	676
2026 Q1	$172K	Buy	+12,387	New	+$197K	﹤0.01%	1151
2023 Q3	–	Sell	-15,027	Closed	-$101K	–	970
2023 Q2	$101K	Buy	15,027 +841	+6%	+$6.25K	﹤0.01%	913
2023 Q1	$125K	Sell	14,186 -11,226	-44%	-$99K	﹤0.01%	818
2022 Q4	$194K	Buy	+25,412	New	+$198K	0.01%	729
2022 Q3	–	Sell	-19,045	Closed	-$154K	–	838
2022 Q2	$154K	Buy	+19,045	New	+$167K	0.01%	644

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Quadrature Capital's ADPT Position: Q2 2026 in Review

Quadrature Capital increased its Adaptive Biotechnologies (ADPT) stake by 351% in Q2 2026, buying an estimated $665K and bringing the position to 55,823 shares worth $1.2M. The position accounts for 0.01% of the portfolio, ranked #676.

Quadrature Capital first reported a position in ADPT in Q2 2022 and has held it in 6 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Quadrature Capital held 55,823 shares of Adaptive Biotechnologies worth $1.2M as of Q2 2026.
Quadrature Capital bought 43,436 Adaptive Biotechnologies shares in Q2 2026, an estimated $665K.
Adaptive Biotechnologies made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #676 holding.
Quadrature Capital first reported a position in Adaptive Biotechnologies in Q2 2022 and has held it in 6 quarters since.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.